We have previously demonstrated that human H2-relaxin can mediate androgen-independent growth of LNCaP through a mechanism that involves the activation of the androgen receptor (AR) signaling pathway. The goal of the current study is to elucidate the mechanism(s) by which H2-relaxin causes activation of the AR pathway. Our data indicate that there is cross-talk between AR and components of the Wnt signaling pathway. Addition of H2-relaxin to LNCaP cells resulted in increased phosphorylation of protein kinase B (Akt) and inhibitory phosphorylation of glycogen synthase kinase-3b (GSK-3b) with subsequent cytoplasmic accumulation of b-catenin. Immunoprecipitation and immunocytochemical studies demonstrated that the stabilized b-catenin formed a complex with AR, which was then translocated into the nucleus. Chromatin immunoprecipitation analysis determined that the AR/b-catenin complex binds to the proximal region of the prostatespecific antigen promoter. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3b and translocation of b-catenin/AR into the nucleus. Knockdown of b-catenin levels using a b-cateninspecific small interfering RNA inhibited H2-relaxin-induced AR activity. The combined data demonstrate that PI3K/ Akt and components of the Wnt pathway can facilitate H2-relaxin-mediated activation of the AR pathway.
Introduction
H2-relaxin is a small peptide hormone structurally related to the insulin family (Ivell, 2002) . It is produced by the ovary and/or placenta in pregnant women and the prostate in men and has shown to be essential for the proper development and function of these systems (Sherwood, 2004) . LGR7, a G protein-coupled receptor (GPCR), mediates the action of H2-relaxin (Hsu et al., 2002) . Recent studies have demonstrated that overexpression of H2-relaxin can promote tumorigenesis in prostate by enhancing tumor cell growth, invasion and angiogenesis (Silvertown et al., 2003) . We previously reported that H2-relaxin induces growth of LNCaP in an androgen-independent (AI) manner through activation of the androgen receptor (AR) (Vinall et al., 2006) . H2-relaxin has been shown to be upregulated during neuroendocrine differentiation of LNCaP prostate cancer cells (Figueiredo et al., 2005) . Androgen depletion/ablation leads to increased level of neuroendocrine cells in vitro (Yuan et al., 2006) and in vivo (Huss et al., 2004) , and abundant literature suggests that increased level of neuroendocrine differentiation in prostate cancer is associated with progression towards an AI state (di Sant'Agnese and Cockett, 1996) . Mutation of p53 is another hallmark of prostate cancer progression (Shi et al., 2004) , the most common mutation found in prostate cancer is p53-R273H (Dinjens et al., 1994) . When stably transfected into androgen-sensitive cell lines, such as LNCaP and PC-346C, this mutant causes an upregulation of H2-relaxin and its receptor LGR7 (Vinall et al., 2006) . Transfection of other p53 mutants (G245S, R248W and R273C) into LNCaP also causes elevation of H2-relaxin expression (Vinall et al., 2006) . How H2-relaxin contributes to AR activation and AI growth is completely unknown. Studies in other systems revealed that H2-relaxin activates the cAMP pathway in a tyrosine kinase-dependent manner (Bartsch et al., 2001) . Using THP-1 cell line as a model, it was shown that H2-relaxin also stimulates protein kinase C zeta, as well as PI3 kinase, via both Gs and Gi proteins (Dessauer and Nguyen, 2005; Halls et al., 2005b) . These studies provide important basic information concerning the signal pathways emanating from H2-relaxin and set the stage for the present study in prostate cancer cells.
In prostate cancer, an increase in b-catenin expression level correlates with disease progression. b-Catenin was originally identified as a component of adherent junctions that facilitated the binding of cadherins and the actin cytoskeleton (Song et al., 2004) . Subsequent studies revealed that b-catenin is part of Wnt pathway and plays a role in signal transduction (Nusse, 2005) . b-Catenin serves as a co-activator of T-cell factor (TCF)/lymphoid enhancing factor, a transcription factor, implicated in growth and early development (Eastman and Grosschedl, 1999) . Inappropriate activation of Wnt signaling contributes to numerous human cancers (Polakis, 2000; Reya and Clevers, 2005) . In prostate cancer, Wnt3a induces AR-mediated transcription and AI growth of LNCaP cell line, in a b-catenin-dependent manner (Verras et al., 2004) . Other studies showed that b-catenin is associated with AR and acts as an AR co-activator to enhance AR-mediated transcription (Truica et al., 2000; Yang et al., 2002) . Indeed, in prostate cancer cell lines LNCaP and CWR22Rv1, the b-catenin-mediated AR response seems to dominate over the TCF response, and requires lower levels of b-catenin for activation (Cronauer et al., 2005) . In addition to being a co-activator of AR, b-catenin is able to modulate both the transcription and protein stability of AR in a complex fashion (Yang et al., 2006) . Thus, there is strong evidence linking b-catenin to AR activity and prostate cancer growth.
In this report, we show that H2-relaxin enhances AR activity via activation of b-catenin, which is accompanied by phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) activation and phosphorylation/degradation of glycogen synthase kinase-3b (GSK-3b). To our knowledge, this is the first report that connects the relaxin/ GPCR pathway to the Wnt pathway.
Results

H2-relaxin induces activation of Akt and the phosphorylation of GSK-3b
To understand the mechanism whereby H2-relaxin activates AR, we first looked for GPCR signals elevated in LNCaP-R273H, as compared to wild-type LNCaP. After preliminary screening with phospho-specific antibodies against different signal molecules, we found that the phosphorylation of Akt (Ser473) was consistently elevated in the LNCaP-R273H subline (Figure 1 ). The data are in agreement with the ability of the Gbg subunits of GPCR to activate PI3K/Akt (Stoyanov et al., 1995; Murga et al., 1998) . We noted that a basal level of phospho-Akt was detected in parental LNCaP, presumably due to the inactivating mutation of PTEN in this cell line (Vlietstra et al., 1998) . The combined effect of H2-relaxin expression and PTEN deficiency resulted in the hyperactivation of Akt in LNCaP-R273H. This is accompanied by the increase of the inhibitory-phosphorylation of GSK-3b at Ser9 (Figure 1 ).
H2-relaxin induces Akt and GSK-3b phosphorylation in LNCaP cells
LNCaP cells were treated with H2-relaxin (100 ng/ml) for 0.5, 1, 3 and 6 h, and the levels of phospho-Akt and phospho-GSK-3b were assessed to determine whether H2-relaxin could increase the phosphorylation of these molecules in a time-dependent manner. Phosphorylation of Akt at Thr308 peaked at 30 min after H2-relaxin treatment. Phosphorylation at Ser473 occurred as soon as 30 min post-treatment and peaked at 180 min. Phosphorylation of GSK-3b Ser9 followed a similar kinetics ( Figure 2 ). These data provide strong evidence that H2-relaxin is able to activate the Akt pathway.
H2-relaxin increases b-catenin levels and the association of b-catenin with AR GSK-3b is a kinase, which causes destabilization of b-catenin by phosphorylating it at Ser33, 37 and Thr41 (Yost et al., 1996) . The phosphorylated b-catenin is then degraded by the ubiquitin/proteasome pathway. Phosphorylation of GSK-3b at Ser9 reduces the activity of GSK-3b resulting in decreased degradation of b-catenin and the subsequent accumulation of b-catenin in the cytoplasm and translocation into the nucleus Morin et al., 1997) . Western blot analysis showed that treatment of LNCaP cells with H2-relaxin for 0.5 h resulted in decreased phosphorylation of b-catenin and a corresponding increase of the b-catenin protein level (Figure 3a ). Increasing evidence suggests that stabilized b-catenin serves as a co-activator of AR (Truica et al., 2000; Yang et al., 2002) . To determine whether H2-relaxin-stabilized b-catenin can interact with AR, protein extracts from LNCaP treated with or without H2-relaxin were immunoprecipitated with an AR antibody followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and western blot analysis with an antibody to b-catenin. Figure 3b LNCaP LNCaP R273H
Akt Figure 1 The phosphorylation of Akt and GSK-3b in LNCaP and LNCaP-R273H cells. Cells were serum starved overnight. Lysates were analysed in immunoblotting with anti-p-Akt (Ser473), Akt, p-GSK-3b (Ser9) and GSK-3b. Total Akt and GSK-3b were used as internal loading controls. Akt, protein kinase B; GSK-3b, glycogen synthase kinase-3b.
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showed that treatment of LNCaP with H2-relaxin increased the level of association between b-catenin and AR. Immunochemical analysis substantiated the above result and showed that H2-relaxin treatment of LNCaP cells increased not only b-catenin accumulation in the cytoplasm but also AR and b-catenin colocalization in the nucleus (Figure 3c ).
H2-relaxin induces the recruitment of b-catenin to PSA promoter
We next proceeded to determine whether H2-relaxininduced b-catenin/AR complex was recruited to relevant promoters targeted by AR (for example, prostatespecific antigen (PSA) promoter). Chromatin immunoprecipitation (ChIP) assay was employed for this analysis. We analysed both the proximal (P) androgen receptor response element (ARE) I/II and the distal enhancer (E) ARE III sites for potential binding to the b-catenin/AR complex. The region in between, H, was used as a negative control. Interestingly, H2-relaxin induced b-catenin binding to the proximal (P) region of the PSA promoter, but not to the PSA enhancer (E) region or the PSA H region (Figure 4 ). By contrast, dihydrotestosterone (DHT) induced the recruitment of b-catenin to both the P and E sites. This is consistent with reports by us and others that post-translationally activated AR, unlike androgen bound receptor, only binds the proximal ARE and not the distal ARE ( 
LY294002 blocks H2-relaxin-induced phosphorylation of Akt and GSK-3b and the colocalization of AR and b-catenin in the nucleus
To confirm that PI3K is involved in H2-relaxinmediated AR activation, we used the PI3K inhibitor LY294002 to block PI3K/Akt activation. We hypothesized that inhibition of the PI3K/Akt pathway would prevent the interaction of AR and b-catenin in LNCaP-R273H cells. Indeed, the association and colocalization of b-catenin and AR could be blocked by treatment with LY294002 (Figure 5a ), even in the presence of 200 ng/ml H2-relaxin (data not shown). To determine whether this observation was due to LY294002-induced changes in the intracellular level of b-catenin protein, we examined both AR and b-catenin protein levels using western blotting. LY294002 treatment did not significantly affect AR protein level, but inhibited the accumulation of b-catenin induced by H2-relaxin ( Figure 5b ). These results together indicate that inhibition of PI3K can suppress H2-relaxin-mediated association of AR and b-catenin through decreasing b-catenin protein level. Consistent with the decrease in b-catenin protein levels, we found that H2-relaxin-mediated Ser9 phosphorylation of GSK-3b proteins was also impaired by treatment with LY294002 in a dose-dependent manner (Figure 5c ). Likewise, complete inhibition of H2-relaxin-induced Akt phosphorylation at sites Thr308 and Ser473 was observed in samples treated with LY294002 at a concentration above 12.5 mM. The total amount of Akt and GSK-3b proteins remained the same in the presence or absence of LY294002.
b-Catenin siRNA blocks H2-relaxin-mediated AR activation Our previous results suggest that H2-relaxin is able to influence the AR signaling pathway. Transient transfection assays were performed to further investigate the possible effect of b-catenin on AR-mediated transcription. Plasmids capable of expressing a PSA luciferase reporter and a b-catenin-specific small interfering RNA (siRNA) were transfected into LNCaP cells. H2-relaxin treatment induced a nearly 1.5-fold increase in transactivation in LNCaP cells. Co-transfection of the b-catenin siRNA decreased AR activity induced by H2-relaxin to base line ( Figure 6 ). These data indicate that b-catenin is a critical component in H2-relaxin-mediated AR activation. Conversely, we were able to show that overexpression of b-catenin can directly augment the transcriptional activity of AR, using a b-catenin expression construct (Pang et al., 1997) . As seen in Figure 6 , elevated levels of b-catenin enhanced both basal as well as H2-relaxin-mediated AR transcription through the PSA promoter.
Discussion
We previously showed that LNCaP-R273H, a LNCaP subline that expresses a high level of H2-relaxin, is able Figure 2 Phosphorylation of Akt and GSK-3b induced by H2-relaxin in LNCaP cells. LNCaP cells were serum starved overnight and treated with 100 ng/ml H2-relaxin for different time points varying from 0.5 to 6 h. Lysates were analysed by immunoblotting with anti-p-Akt (Thr308), p-Akt (Ser473), Akt, p-GSK-3b (Ser9) and GSK-3b. Total Akt and GSK-3b were used as internal loading controls. Akt, protein kinase B; GSK-3b, glycogen synthase kinase-3b.
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to grow in the absence of androgen in vitro (Nesslinger et al., 2003) , and that H2-relaxin treatment of wild-type LNCaP resulted in its AI growth via AR activation (Vinall et al., 2006) . While virtually nothing is known about the signals engaged by H2-relaxin in prostate cancer cells, previous work in other systems has provided an outline of the pathways involved. Upon H2-relaxin treatment, cAMP, tyrosine kinases, PI3K/ Akt and Erk pathways are stimulated in a cell-contextdependent manner (Palejwala et al., 1998; Hsu et al., 2002; Zhang et al., 2002; Nguyen et al., 2003; Dessauer and Nguyen, 2005) . We have surveyed some of these pathways, and found that the Akt activation, as reflected by increased phosphorylation at the PDK1 site and the autokinase site, was most pronounced. In addition, the phosphorylation of GSK-3b, a downstream effector of Akt was increased and this phosphorylation (at Ser9) inhibits the kinase activity of GSK-3b (Cross et al., 1995) . GSK-3b is a component of the Wnt signaling pathway, which regulates the stability of b-catenin (Nusse, 1997) . GSK-3b destabilizes b-catenin by phosphorylating it at Ser33, 37 and Thr41, with subsequent recognition by the ubiquitin/proteasome degradation system (Yost et al., 1996) . The Aktmediated phosphorylation and inactivation of GSK-3b should result in the stabilization of b-catenin. This was exactly what we observed in both LNCaP-R273H and 
PSA-P PSA-E
PSA-H Input β-catenin AR Figure 4 H2-relaxin induced b-catenin recruitment to PSA promoter. LNCaP cells were treated with vehicle, 10 nM DHT or 100 ng/ml H2-relaxin in serum-free medium overnight. ChIP assay was performed using anti-AR, anti-b-catenin antibodies to immunoprecipitate protein-DNA complex. PCR reactions products, including P domain, E domain and H domain of PSA promoter, were observed from input control DNA, anti-b-catenin and anti-AR immunoprecipitated chromatin from vehicle, DHT and H2-relaxin treated LNCaP cells in ethidium bromide-stained agarose gel. AR, androgen receptor; ChIP, chromatin immunoprecipitation; DHT, dihydrotestosterone; PSA, prostate-specific antigen.
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LNCaP treated with H2-relaxin. To our knowledge, this is the first time that b-catenin stabilization induced by relaxin has been described. The overall proposed pathway leading to b-catenin accumulation is summarized in Figure 7 . We presume the initial activation of PI3K is caused by the free Gbg (Castellone et al., 2005) , coupled with the PTEN deletion in this cell line. An alternative pathway is via Gas, where its association with axin would release GSK-3b, resulting in the stabilization of b-catenin. This scenario is unlikely to operate in LNCaP cells, since they express an undetectable level of axin (data not shown). Previous studies showed that b-catenin can augment AR activity through a specific AR/b-catenin protein-protein interaction (Yang et al., 2002) . In the current study, we found that H2-relaxin induced the association of b-catenin with AR through b-catenin stabilization and subsequent translocation of this complex into the nucleus (Figure 3c ). This was echoed by the constitutive colocalization of AR and b-catenin in LNCaP-R273H cells. The involvement of the PI3K/Akt pathway in causing this colocalization was further confirmed by the application of LY294002 to H2-relaxin-treated LNCaP or LNCaP-R273H; in both cases, the accumulation of b-catenin, the association of AR with b-catenin and their translocation into the nucleus of these cells were blocked. The consequence of increased association between b-catenin and AR is the increased activity of AR in the transcription of target genes (Truica et al., 2000) . In the literature, the b-catenin effect is mostly observed with liganded AR. Our data indicate that b-catenin can augment AR transcription in an AI manner. Nonetheless, we anticipate that the effect of H2-relaxin may be even more pronounced in the presence of androgen. In summary, we provide evidence that H2-relaxin acts as an upstream signal to induce the transcriptional (c) LNCaP-R273H cells were serum starved overnight, pretreated with or without LY294002 at varying concentration for 0.5 h, and then treated with 200 ng/ml H2-relaxin for 3 h. Lysates were analysed by immunoblotting with anti-p-Akt (Thr308), p-Akt (Ser473), Akt, p-GSK-3b (Ser9) and GSK-3b. b-Actin was used as an internal loading control. Akt, protein kinase B; AR, androgen receptor; DAPI, 4,6-diaminidino-2-phenylindole; GSK-3b, glycogen synthase kinase-3b.
Inappropriate activation of AR by relaxin S Liu et al activity of AR and the growth of prostate cancer cells through increased expression of b-catenin. Our study further connects the GPCR and Wnt signaling pathways to AR activation and the development of hormone refractory prostate cancer.
Materials and methods
Cell lines and treatments
LNCaP and LNCaP-R273H cells were routinely maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum. Before treatment with H2-relaxin, cells were cultured in phenol red-free RPMI-1640 medium without serum for 12 h. In the experiments with the PI3 kinase inhibitor, cells were pre-treated with various concentrations of LY294002 (Cell Signaling Technology, Inc., Beverley, MA, USA) in dimethyl sulfoxide for 30 min and followed by 100 ng/ml H2-relaxin treatment for 3 h.
Antibodies
Mouse antibodies against AR (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and b-actin (Sigma, St Louis, MO, USA), rabbit antibodies against GSK-3b, phospho-GSK3b (Ser 9), Akt, phospho-Akt (Thr 308 or Ser 473), b-catenin, phospho-b-catenin (Ser 33/37/Thr 41) (Cell Signaling), Gas and axin were used for immunoprecipitation, western blotting and immunofluorescence analysis.
ChIP assay
ChIP assay was performed as described previously (Vinall et al., 2006) , as well as, primers for the PSA promoter region (Louie et al., 2003) .
Western blot analysis and immunoprecipitation
The methods for isolation of cell lysate, western blot analysis and immunoprecipitation have been described previously (Desai et al., 2006; Vinall et al., 2006) .
Supplementary methods
Detailed descriptions of immunofluorescence microscopy, siRNA and luciferase assays are provided in Supplementary methods. LGR7 receptors that are coupled to heterotrimeric G proteins of the Gas family. Upon exchange of GDP for GTP, free bg subunits stimulate the PI3K-PDK1-Akt signaling pathway (right), which causes the phosphorylation and inactivation of GSK-3b. These events lead to b-catenin stability, AR association with b-catenin and expression of growth-promoting genes regulated by AR transcription factors. H2-relaxin can also increase cAMP level through Gas signaling pathway (Hsu et al., 2002) , activate PKA (Halls et al., 2005a) and Erk pathways (Zhang et al., 2002; Dessauer and Nguyen, 2005 ) (left). AR, androgen receptor; GSK-3b, glycogen synthase kinase-3b. Figure 6 Inhibition of H2-relaxin-mediated AR transcription activity by b-catenin siRNA. LNCaP cells were transfected with PSA-luciferase reporter plasmid (100 ng), pRL-SV40 renilla luciferase plasmid (25 ng) and b-catenin-specific siRNA (100 nM) or pcDNA3.1-b-catenin (50 ng). After transfection for 24 h, cells were treated with or without 100 ng/ml H2-relaxin in serum-free medium for 24 h. Cell lysates were measured for luciferase activities. The data represent the mean of three independent samples. AR, androgen receptor; siRNA, small interfering RNA; PSA, prostate-specific antigen.
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